Drug Trial Radar · NCT01127581
Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery
Last checked: Nov 20, 2026Latest source record: May 1, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,358
Actual
Start
Sep 2010
Primary completion
Mar 2012
Study completion Mar 2012
Sponsor
- Lead sponsor
- Ferring PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- May 21, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether the Misoprostol Vaginal Insert (MVI) 200 microgram (mcg) can decrease the time to vaginal delivery compared to the Dinoprostone Vaginal Insert (DVI) 10 milligram (mg) in pregnant women requiring cervical ripening and induction of labor.
Conditions
- Reducing Time to Vaginal Delivery
- Cervical Ripening
- Induction of Labor
Interventions
MVI 200Drug
Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Dinoprostone Vaginal Insert (DVI)Drug
Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Vaginal Delivery During the First Hospital AdmissionTime frame: Interval from study drug administration to vaginal delivery (average 24 hours)
- Incidence of Cesarean Delivery During the First Hospital AdmissionTime frame: Interval from study drug administration to cesarean delivery (average 24 hours)
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
Maricopa Medical Center - District Medical Group
Phoenix, Arizona
Precision Trials
Phoenix, Arizona
Phoenix Perinatal Associates (Scottsdale Healthcare Shea)
Scottsdale, Arizona
Watching Over Mothers and Babies Foundation
Tucson, Arizona
Miller's Childrens Hospital
Long Beach, California
UCI Medical Center
Orange, California
The Women's Clinic of Northern Colorado
Fort Collins, Colorado
Christiana Care Health System (DE Center for MFM)
Newark, Delaware
University of FL College of Medicine
Jacksonville, Florida
Altus Research
Lake Worth, Florida
University of South Florida
Tampa, Florida
Indiana University School of Medicine
Indianapolis, Indiana
University of Kansas School of Medicine
Kansas City, Kansas
University of Michigan Hospital
Ann Arbor, Michigan
Spectrum Health
Grand Rapids, Michigan
St. Louis University
St Louis, Missouri
St. Peters University Hospital
New Brunswick, New Jersey
University of New Mexico/New Mexico Health Science Center
Albuquerque, New Mexico
Duke University Medical Center
Durham, North Carolina
East Carolina University, Brody School of Medicine
Greenville, North Carolina
Lyndhurst Gynecologic Associates
Winston-Salem, North Carolina
University of Cincinnati
Cincinnati, Ohio
Clinical Trials of America
Eugene, Oregon
Drexel University College of Medicine
Philadelphia, Pennsylvania
Temple University School of Medicine
Philadelphia, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
University Medical Group/Greenville Hospital System
Greenville, South Carolina
UT College of Medicine Chattanooga, Erlanger Health System
Chattanooga, Tennessee
High Risk Obstetrical Consultants, PLLC
Knoxville, Tennessee
Research Memphis Associates
Memphis, Tennessee
University of Texas Health Sciences Center at Houston
Houston, Texas
Salt Lake Women's Center, PC
Sandy City, Utah
Marshfield Clinic Research Foundation
Marshfield, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.